References
- Johnston L J, Horning S J. Autologous hematopoietic cell transplantation in Hodgkin's disease. Biol Blood Marrow Transplant 2000; 6: 289–300
- Tarella C, Cuttica A, Vitolo U, Liberati M, Di Nicola M, Cortelazzo S, et al. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence. Cancer 2003; 97: 2748–2759
- Linch D C, Winfield D, Goldstone A H, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051–1054
- Schmitz N, Pfistner B, Sextro M, Sieber M, Carella A M, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065–2071
- Vose J M, Bierman P J, Anderson J R, Kessinger A, Pierson J, Nelson J, et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 1992; 80: 2142–2148
- Shamash J, Lee S M, Radford J A, Rohatiner A Z, Chang J, Morgenstern G R, et al. Patterns of relapse and subsequent management following high-dose chemotherapy with autologous haematopoietic support in relapsed or refractory Hodgkin's lymphoma: a two centre study. Ann Oncol 2000; 11: 715–719
- Santoro A, Bredenfeld H, Devizzi L, Tesch H, Bonfante V, Viviani S, et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol 2000; 18: 2615–2619
- Anderson J E, Litzow M R, Appelbaum F R, Schoch G, Fisher L D, Buckner C D, et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J Clin Oncol 1993; 11: 2342–2350
- Gajewski J L, Phillips G L, Sobocinski K A, Armitage J O, Gale R P, Champlin R E, et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 1996; 14: 572–578
- Milpied N, Fielding A K, Pearce R M, Ernst P, Goldstone A H. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 1996; 14: 1291–1296
- Peggs K S, Hunter A, Chopra R, Parker A, Mahendra P, Milligan D, et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005; 365: 1934–1941
- Avalos B R, Copelan E A. Second autologous bone marrow transplantation in Hodgkin's disease. Bone Marrow Transplant 1993; 12: 665–667
- Lin T S, Avalos B R, Penza S L, Marcucci G, Elder P J, Copelan E A. Second autologous stem cell transplant for multiply relapsed Hodgkin's disease. Bone Marrow Transplant 2002; 29: 763–767
- Vandenberghe E, Pearce R, Taghipour G, Fouillard L, Goldstone A H. Role of a second transplant in the management of poor-prognosis lymphomas: a report from the European Blood and Bone Marrow Registry. J Clin Oncol 1997; 15: 1595–1600
- Horning S J, Hoppe R T, Breslin S, Bartlett N L, Brown B W, Rosenberg S A. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002; 20: 630–637
- Diehl V, Behringer K. Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma (HL)?. Cancer Invest 2000; 24: 713–717